Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non–small cell lung cancer
- 13 September 2017
- journal article
- letter
- Published by Elsevier BV in European Journal of Cancer
- Vol. 85, 155-157
- https://doi.org/10.1016/j.ejca.2017.07.049
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyThe Lancet Oncology, 2016
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationNature Reviews Clinical Oncology, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialAnnals of Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015